KPRX News and Press, Kiora Pharmaceuticals Inc.

Encinitas, California--(Newsfile Corp. - July 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), today announced that Eric Daniels, M.D., Chief Development Officer, will present at the Jones Trading Healthcare Seaside Summit on Monday, July 15 at 6:15 pm Eas...

Ken Gayron to Step Down as a Member of the Company's Board Encinitas, California--(Newsfile Corp. - July 1, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's Board of ...

Encinitas, California--(Newsfile Corp. - June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to its Scientific Advisory Board. As an advisor, Dr. Goldberg will contribute scientific insights a...

Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...

Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00...

2024-05-10 07:23:29 ET More on Kiora Pharmaceuticals Seeking Alpha’s Quant Rating on Kiora Pharmaceuticals Historical earnings data for Kiora Pharmaceuticals Financial information for Kiora Pharmaceuticals Read the full article on Seeking Alpha ...

Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024 Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 Ended Q1 2024 with $31.3 million in cash and cash eq...

Encinitas, California--(Newsfile Corp. - May 8, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at The Citizens JMP Life Sciences Conference on Tuesday May 14 th , 2024 at 1:00 pm EDT. Kiora's presentations can be accessed live from the ho...

Previously released ABACUS-1 clinical trial results reported KIO-301, a small molecule photoswitch, is safe, tolerable, and improved vision in patients with late-stage retinitis pigmentosa. Additional analysis of functional MRI data demonstrated a statistically significant increase in neural ...

Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for patients with profound blindness. Functional vision assess...